ASX listed Biotech upstart PharmAust says that its ongoing clinical research in Melbourne is demonstrating that its anti-cancer drug, Monepantel’s principle end-product, metabolite Monepantel Sulfone, retains the same biological activity as the drug itself. The metabolite shows little side effects upon healthy, non-cancerous cells and works together with Monepantel, producing a “double kick” in eliminating cancer cells. Reduced dosing treatments are envisaged for upcoming canine and human trials.